Licarin A, a neolignan isolated from Nectandra oppositifolia Nees & Mart. (Lauraceae), exhibited moderate preclinical efficacy against Schistosoma mansoni infection

Schistosomiasis is a widespread human parasitic disease currently affecting over 200 million people, particularly in poor communities. Chemotherapy for schistosomiasis relies exclusively on praziquantel (PZQ). Previous studies have shown that licarin A (LIC‐A), a dihydrobenzofuran neolignan, exhibit...

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy research 2021-09, Vol.35 (9), p.5154-5162
Main Authors: Mengarda, Ana C., Silva, Marcos P., Cirino, Maria E., Morais, Thiago R., Conserva, Geanne A. A., Lago, João Henrique G., Moraes, Josué
Format: Article
Language:English
Subjects:
Animal models
Antiparasitic agents
antischistosomal activity
Chemotherapy
Eggs
Lauraceae
Lead compounds
licarin A
lignan
Low income areas
Metabolites
Nectandra
Nectandra oppositifolia
Oral administration
Parasites
Parasitic diseases
Praziquantel
schistosoma
Schistosoma mansoni
Schistosomiasis
Splenomegaly
Tropical diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Schistosomiasis is a widespread human parasitic disease currently affecting over 200 million people, particularly in poor communities. Chemotherapy for schistosomiasis relies exclusively on praziquantel (PZQ). Previous studies have shown that licarin A (LIC‐A), a dihydrobenzofuran neolignan, exhibited in vitro antiparasitic activity against Schistosoma mansoni adult worms. This study aimed to investigate the potential of LIC‐A, isolated as main metabolite from leaves of Nectandra oppositifolia Nees & Mart. (Lauraceae), as an antischistosomal agent orally active in schistosomiasis animal model. PZQ was used as a reference compound. As result, LIC‐A showed, at a single dose of 400 mg/kg, to be able to partially cure infected mice (worm burden reductions of ~50%). Parasite eggs, that are responsible for a variety of pathologies and transmission of schistosomiasis, were also moderately inhibited by LIC‐A (egg burden reductions of ~50%–60%). Furthermore, it was observed that LIC‐A achieved a slight reduction of hepatomegaly and splenomegaly. Collectively, although LIC‐A was partially active when administered orally, these results give support for the antiparasitic potential LIC‐A as lead compound for novel antischistosomal agent.
ISSN:0951-418X
1099-1573
DOI:10.1002/ptr.7184